Protection by Vaccines and Previous Infection Against the
Omicron Variant of Severe Acute Respiratory Syndrome
Coronavirus 2

J 2022

Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2

ŠMÍD, Martin, Luděk BEREC, Lenka PŘIBYLOVÁ, Ondřej MÁJEK, Tomáš PAVLÍK et. al.

Základní údaje

Originální název

Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2

Autoři

ŠMÍD, Martin (garant), Luděk BEREC, Lenka PŘIBYLOVÁ (203 Česká republika, domácí), Ondřej MÁJEK (203 Česká republika, domácí), Tomáš PAVLÍK (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Jakub WEINER, Tamara BARUSOVÁ a Jan TRNKA

Vydání

The Journal of Infectious Diseases, Oxford University Press, 2022, 0022-1899

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30303 Infectious Diseases

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.400

Kód RIV

RIV/00216224:14110/22:00126263

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1093/infdis/jiac161

UT WoS

000805341600001

Klíčová slova anglicky

COVID-19; postinfection immunity; vaccine effectiveness; SARS-CoV-2; Omicron variant; hospitalization

Štítky

14119612, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 3. 2023 12:30, Mgr. Tereza Miškechová

Anotace

V originále

Background The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evades immunity conferred by vaccines and previous infections. Methods We used a Cox proportional hazards model and a logistic regression on individual-level population-wide data from the Czech Republic to estimate risks of infection and hospitalization, including severe states. Results A recent (≤2 months) full vaccination reached vaccine effectiveness (VE) of 43% (95% confidence interval [CI], 42%–44%) against infection by Omicron compared to 73% (95% CI, 72%–74%) against Delta. A recent booster increased VE to 56% (95% CI, 55%–56%) against Omicron infection compared to 90% (95% CI, 90%–91%) for Delta. The VE against Omicron hospitalization of a recent full vaccination was 45% (95% 95% CI, 29%–57%), with a recent booster 87% (95% CI, 84%–88%). The VE against the need for oxygen therapy due to Omicron was 57% (95% CI, 32%–72%) for recent vaccination, 90% (95% CI, 87%–92%) for a recent booster. Postinfection protection against Omicron hospitalization declined from 68% (95% CI, 68%–69%) at ≤6 months to 13% (95% CI, 11%–14%) at >6 months after a previous infection. The odds ratios for Omicron relative to Delta were 0.36 (95% CI, .34–.38) for hospitalization, 0.24 (95% CI, .22–.26) for oxygen, and 0.24 (95% CI, .21–.28) for intensive care unit admission. Conclusions Recent vaccination still brings substantial protection against severe outcome for Omicron.

Citovat

ŠMÍD, Martin, Luděk BEREC, Lenka PŘIBYLOVÁ, Ondřej MÁJEK, Tomáš PAVLÍK, Jiří JARKOVSKÝ, Jakub WEINER, Tamara BARUSOVÁ a Jan TRNKA. Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2. The Journal of Infectious Diseases. Oxford University Press, 2022, roč. 226, č. 8, s. 1385-1390. ISSN 0022-1899. Dostupné z: https://dx.doi.org/10.1093/infdis/jiac161.

@article{1874687,
   author = {Šmíd, Martin and Berec, Luděk and Přibylová, Lenka and Májek, Ondřej and Pavlík, Tomáš and Jarkovský, Jiří and Weiner, Jakub and Barusová, Tamara and Trnka, Jan},
   article_number = {8},
   doi = {http://dx.doi.org/10.1093/infdis/jiac161},
   keywords = {COVID-19; postinfection immunity; vaccine effectiveness; SARS-CoV-2; Omicron variant; hospitalization},
   language = {eng},
   issn = {0022-1899},
   journal = {The Journal of Infectious Diseases},
   title = {Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2},
   url = {https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiac161/6575414?login=true},
   volume = {226},
   year = {2022}
}

TY  - JOUR
ID  - 1874687
AU  - Šmíd, Martin - Berec, Luděk - Přibylová, Lenka - Májek, Ondřej - Pavlík, Tomáš - Jarkovský, Jiří - Weiner, Jakub - Barusová, Tamara - Trnka, Jan
PY  - 2022
TI  - Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2
JF  - The Journal of Infectious Diseases
VL  - 226
IS  - 8
SP  - 1385-1390
EP  - 1385-1390
PB  - Oxford University Press
SN  - 00221899
KW  - COVID-19
KW  - postinfection immunity
KW  - vaccine effectiveness
KW  - SARS-CoV-2
KW  - Omicron variant
KW  - hospitalization
UR  - https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiac161/6575414?login=true
N2  - Background The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evades immunity conferred by vaccines and previous infections. Methods We used a Cox proportional hazards model and a logistic regression on individual-level population-wide data from the Czech Republic to estimate risks of infection and hospitalization, including severe states. Results A recent (≤2 months) full vaccination reached vaccine effectiveness (VE) of 43% (95% confidence interval [CI], 42%–44%) against infection by Omicron compared to 73% (95% CI, 72%–74%) against Delta. A recent booster increased VE to 56% (95% CI, 55%–56%) against Omicron infection compared to 90% (95% CI, 90%–91%) for Delta. The VE against Omicron hospitalization of a recent full vaccination was 45% (95% 95% CI, 29%–57%), with a recent booster 87% (95% CI, 84%–88%). The VE against the need for oxygen therapy due to Omicron was 57% (95% CI, 32%–72%) for recent vaccination, 90% (95% CI, 87%–92%) for a recent booster. Postinfection protection against Omicron hospitalization declined from 68% (95% CI, 68%–69%) at ≤6 months to 13% (95% CI, 11%–14%) at >6 months after a previous infection. The odds ratios for Omicron relative to Delta were 0.36 (95% CI, .34–.38) for hospitalization, 0.24 (95% CI, .22–.26) for oxygen, and 0.24 (95% CI, .21–.28) for intensive care unit admission. Conclusions Recent vaccination still brings substantial protection against severe outcome for Omicron.
ER  -

ŠMÍD, Martin, Luděk BEREC, Lenka PŘIBYLOVÁ, Ondřej MÁJEK, Tomáš PAVLÍK, Jiří JARKOVSKÝ, Jakub WEINER, Tamara BARUSOVÁ a Jan TRNKA. Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2. \textit{The Journal of Infectious Diseases}. Oxford University Press, 2022, roč.~226, č.~8, s.~1385-1390. ISSN~0022-1899. Dostupné z: https://dx.doi.org/10.1093/infdis/jiac161.

Podrobný výpis o publikaci